Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;14(4):1210-1221.
doi: 10.1111/cts.13050. Epub 2021 May 7.

Reimagining the peer-review system for translational health science journals

Affiliations
Review

Reimagining the peer-review system for translational health science journals

Elise M Smith. Clin Transl Sci. 2021 Jul.

Abstract

Retractions of coronavirus disease 2019 (COVID-19) papers in high impact journals, such as The Lancet and the New England Journal of Medicine, have been panned as major scientific fraud in public media. The initial reaction to this news was to seek out scapegoats and blame individual authors, peer-reviewers, editors, and journals for wrong doing. This paper suggests that scapegoating a few individuals for faulty science is a myopic approach to the more profound problem with peer-review. Peer-review in its current limited form cannot be expected to adequately address the scope and complexity of large interdisciplinary science research collaboration, which is central in translational research. In addition, empirical studies on the effectiveness of traditional peer-review reveal its very real potential for bias and groupthink; as such, expectations regarding the capacity and effectiveness of the current peer review process are unrealistic. This paper proposes a new vision of peer-review in translational science that, on the one hand, would allow for early release of a manuscript to ensure expediency, whereas also creating a forum or a collective of various experts to actively comment, scrutinize, and even build on the research under review. The aim would be to not only generate open discussion and oversight respecting the quality and limitations of the research, but also to assess the extent and the means for that knowledge to translate into social benefit.

PubMed Disclaimer

Conflict of interest statement

The author declared no competing interests for this work.

Similar articles

Cited by

References

    1. Fry CV, Cai X, Zhang Y, Wagner CS. Consolidation in a crisis: patterns of international collaboration in early COVID‐19 research. PLOS ONE. 2020;15(7):e0236307. - PMC - PubMed
    1. Omary MB, Eswaraka J, Kimball SD, et al. The COVID‐19 pandemic and research shutdown: staying safe and productive. J Clin Invest. 2020;130:2745‐2748. - PMC - PubMed
    1. Tsang J, LaManna CM. Open sharing during COVID‐19: CRISPR‐based detection tools. CRISPR J. 2020;3(3):142–145. - PMC - PubMed
    1. Mahase E. Covid‐19: US approves emergency use of convalescent plasma despite warnings over lack of evidence. BMJ. 2020;370:m3327. - PubMed
    1. Arshad U, Pertinez H, Box H, et al. Prioritization of anti‐SARS‐Cov‐2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther. 2020;108:775‐790. - PMC - PubMed

Substances